Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Comment by diadon1945on May 28, 2010 2:42pm
278 Views
Post# 17140989

RE: Tekirma pops on a cure for Ebola Virus

RE: Tekirma pops on a cure for Ebola VirusI checked on AVII... they do not in fact have 100% success with Ebola...as they do with Marburg. Here is what they say.
_____________________________________________________________________________________

In repeated trials, monkeys were dosed with well–tolerated amounts of drug and survived a challenge of roughly 1000 times the minimum lethal dose. This level of infectious challenge normally results in uniform death of untreated monkeys within 7 to 10 days. Treatment of Ebola infected animals with AVI–6002 resulted in 75 percent survival of the infected animals at 15 days post infection when the treatment period ended and circulating viral titer was below detectable levels. Treatment of Marburg infected animals with AVI–6003 resulted in 100 percent survival at 15 days.

The majority of the collaborative research effort between AVI and USAMRIID has been supported by a research contract from the Department of Defense’s Transformational Medical Technologies Initiative (TMTI) with the goal of developing a new antiviral (antisense) platform targeting hemorrhagic fever viruses. In addition to development of antiviral agents for Marburg and Ebola, AVI is receiving government funds to develop antiviral agents to treat Junín virus under this contract. Under separate government agreements, AVI is receiving support for programs in Junin virus, Dengue virus, the H1N1 virus, anthrax and ricin, as well as for additional applications in Ebola and Marburg.

Bullboard Posts